fda glp-1 compounding crackdown september 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our BREAKING NEWS in the compounding

Avoid them at all costs

PubMed 29

12,399 These tools have revolutionized our ability to dissect the biological features of malignant tumor cells, uncover intratumoral heterogeneity and its dynamic evolution, elucidate tumor-immune cell interactions, and uncover mechanisms of drug resistance and relapse, paving the way for personalized treatment strategies to improve patient outcomes (Fig

Several ongoing trials are evaluating whether these agents may influence motor symptoms, cognition, or disease progression in Parkinsons disease patients

Rinvoqs performance was further bolstered by its strategic positioning to offset declining Humira sales due to biosimilar competition

It is ideal for guaranteeing the safety of patients